Klinik Landstrasse
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The research program at Klinik Landstrasse emphasizes innovative strategies to lower the risk of heart attacks, strokes, and related complications in patients with cardiovascular disease. Studies compare novel agents to standard care, aiming to improve outcomes for those with high lipid levels, elevated lipoprotein(a), and advanced arterial disease.
- Acute Myocardial Infarction
- Atherosclerotic Cardiovascular Disease
- Elevated Lp(a)
- Left Ventricular Hypertrophy
- Adults at high risk of cardiovascular events without prior MI or stroke
With three dedicated investigators, the site conducts multiple trials to evaluate the safety and effectiveness of emerging cardiovascular therapies, supporting patients at high risk of recurrent events.
Digestive System Diseases
Clinical investigations target liver health, focusing on non-alcoholic steatohepatitis (NASH) and broader metabolic dysfunction-associated steatotic liver disease. The goal is to determine whether new treatments can improve liver histology and reduce progression to cirrhosis.
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Non-alcoholic steatohepatitis (NASH)
The department leverages its expertise in endocrinology and hepatology to advance therapeutic options for patients with fatty liver conditions.
Nutritional and Metabolic Diseases
Research at the site addresses the growing burden of obesity, overweight, and type 2 diabetes mellitus. Trials explore weight‑loss agents and glucose‑lowering drugs to achieve better metabolic control and reduce associated health risks.
- Obesity
- Overweight
- Overweight and obesity and type 2 diabetes
- Type 2 Diabetes Mellitus
By testing novel combinations and dose regimens, investigators aim to provide safer, more effective options for metabolic disease management.
Metabolism
The department’s metabolic research includes studies on kidney function and albuminuria, seeking therapies that protect renal health while modulating metabolic pathways.
- Chronic Kidney Disease
- Chronic Kidney Disease and Albuminuria
- Hemodialysis
- Kidney Failure
Through collaborative trials, the site evaluates how metabolic interventions can slow disease progression and improve quality of life for patients with renal impairment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Amgen Inc.2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.5trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinik Landstrasse
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis | Merck Sharp & Dohme LLC | Phase II | Not Recruiting | Sep 2023 | Dec 2025 |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 4 | Unknown | 2021-03-29 | 2026-07-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.